Molecular alterations associated with improved survival in pancreatic cancer patients treated with radiation or chemotherapy

Journal of Hepato-Biliary-Pancreatic Surgery

Volumn 5, Issue 3, 1998, Pages 269-272

  Dergham, Sanaa T ^a   Dugan, Michael C ^b   Sarkar, Fazlul H ^a   Vaitkevicius, Vainutis K ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Providence Little Company of Mary Medical Center   (United States)

Author keywords

Adjuvant therapy; Chemotherapy; Gene therapy; K ras; p21WAF 1; p53; Pancreatic cancer; Radiation; Survival

Indexed keywords

CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR; PROTEIN P53;

ADENOCARCINOMA; ARTICLE; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MORTALITY; MUTATION; ONCOGENE RAS; PANCREAS TUMOR; RETROSPECTIVE STUDY; SURVIVAL;

ADENOCARCINOMA; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; MUTATION; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032238257     PISSN: 09441166     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005340050045     Document Type: Article

References (32)

1. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554
2. Smit VTHBM, Boot AJM, Smits AMM (1988) K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinoma. Nucleic Acids Res 16:7773-7782
3. Grunewald K, Lyons J, Frohlich A (1989) High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 43:1037-1041
4. Mariyama M, Kishi K, Nakamura K (1989) Frequency and types of point mutations at the 12th codon of the c-Ki-ras gene found in pancreatic cancer from Japanese patients. Jpn J Cancer Res 80:622-626
5. Nagata Y, Abe M, Motoshima K (1990) Frequent glycine-to-aspartic acid mutations at codon 12 of c-Ki-ras gene in human pancreatic cancer in Japanese. Jpn J Cancer Res 81:135-140
6. Hruban RH, van Mansfeld ADM, Offerhaus GJA, van Weering DHJ, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143:545-554
7. Dergham ST, Kucway R, Dugan MC, Singh K, Biernat L, Vaitkevicius VK, Crissman JD, Sarkar FH (1995) Distribution of K-ras codon 12 substitutions in 100 cases of pancreatic carcinoma (abstract). Pancreas 11:425
8. Ruggeri BA, Huang L, Berger D, Chang H, Klein-Szanto AJP, Goodrow T, Wood M, Obara T, Heath CW, Lynch H (1997) Molecular pathology of primary and metastatic ductal pancreatic lesions; analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer 79:700-716
9. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-353
10. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG (1997) Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57:3126-3130
11. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57:1731-1734
12. Hruban RH, Petersen GM, Ha PK, Kern SE (1998) Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin North Am 7:1-23
13. Dugan MC, Dergham ST, Kucway R, Singh K, Biernat L, Du W, Vaitkevicius VK, Crissman JD, Sarkar FH (1997) HER-2/neu expression in pancreatic adenocarcinoma: Relation to tumor differentiation and survival. Pancreas 14:229-236
14. Dugan MC, Sarkar FH (1998) Molecular markers of in situ neoplasia in the pancreas. In: Sarkar FH, Dugan MC (eds), Chapter 6. Pancreatic cancer: Advances in molecular pathology, diagnosis, and clinical management. Biotechniques Books, Eaton Publishing, Natick, MA
15. Yokoyama M, Yamanaka Y, Friess H, Buchler M, Korc M (1994) p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 14:2477-2483
16. Lundin J, Nordling S, von Boguslawsky K, Roberts PJ, Haglund C (1996) Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology 53:104-111
17. Nakamori S, Yashima K, Murakami Y, Ishikawa O, Ohigashi H, Imaoka S, Yaegashi S, Konishi Y, Sekiya T (1995) Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res 86:174-181
18. Dergham ST, Dugan MC, Kucway R, Du W, Kamarauskiene DS, Vaitkevicius VK, Crissman JD, Sarkar FH (1997) Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int J Pancreatol 21:127-143
19. WAF1/CIP-1 and p53 expression in pancreatic adenocarcinoma. Cancer 80:372-381
20. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495
21. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation on p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311
22. Kasid U, Suy S, Dent P, Ray S, Whiteside TL, Sturgill TW (1996) Activation of Raf by ionizing radiation. Nature 382:813-816
23. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331
24. El-Diery WS, Harper JW, O'Conner PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B (1994) WAF-1/CIP-1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169-1174
25. El Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825
26. Shwartz D, Almog N, Peled A, Goldfinger N, Rotter W (1997) Role wild type p53 in the G2 phase: regulation of the γ-irradiation induced delay and DNA repair. Oncogene 15:2597-2607
27. Martinez JD, Pennington ME, Craven MT, Warters RL, Cress AE (1997) Free radicals generated by ionizing radiation signal nuclear translocation of p53. Cell Growth Differ 8:941-949
28. Li R, Waga S, Hanon GJ, Beach D, Stillman B (1994) Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Exp Cell Res 211:90-98
29. Flores-Rozas H, Kelman Z, Dean FB, pan ZQ, Harper JW, Elledge SJ, O'Donnell M, Huwitz J (1994) Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc Natl Acad Sci USA 91:8655-8659
30. WAF1/Cip1 expression in normal and neoplastic tissues. Cancer Res 55:2910-2919
31. Joshi US, Dergham ST, Chen YQ, Dugan MC, Crissman JD, Vaitkevicius VK, Sarkar FH (1998) Inhibition of pancreatic tumor cell growth in culture by p21WAF1 recombinant adenovirus. Pancreas 16:107-113
32. Mohammad RM, Dugan MC, Mohamed AN, Almatchy VP, Flake TM, Dergham ST, Shields AF, Al-Katib AA, Vaitkevicius VK, Sarkar FH (1998) Establishment of a human pancreatic tumor xenograft model: Potential application for preclinical evaluation of novel therapeutic agents. Pancreas 16:19-25